| __timestamp | Agios Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 3788000000 |
| Thursday, January 1, 2015 | 141827000 | 4006000000 |
| Friday, January 1, 2016 | 220163000 | 4261000000 |
| Sunday, January 1, 2017 | 292681000 | 4371000000 |
| Monday, January 1, 2018 | 1397000 | 4853000000 |
| Tuesday, January 1, 2019 | 1317000 | 4675000000 |
| Wednesday, January 1, 2020 | 2805000 | 4572000000 |
| Friday, January 1, 2021 | 18777000 | 6601000000 |
| Saturday, January 1, 2022 | 1704000 | 5657000000 |
| Sunday, January 1, 2023 | 9504000 | 6498000000 |
| Monday, January 1, 2024 | 4165000 | 28675800000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. Over the past decade, Gilead Sciences, Inc. has consistently outpaced Agios Pharmaceuticals, Inc. in terms of cost of revenue. From 2014 to 2023, Gilead's cost of revenue surged by approximately 72%, peaking in 2021. In contrast, Agios experienced a more volatile trajectory, with a significant drop in 2018, followed by a gradual recovery. By 2023, Gilead's cost of revenue was nearly 700 times that of Agios, highlighting the stark difference in scale and operational scope between the two companies. This disparity underscores Gilead's expansive market reach and robust product pipeline, while Agios continues to navigate the challenges of scaling its operations. As the industry faces new challenges and opportunities, these trends offer valuable insights into the strategic positioning of these pharmaceutical giants.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Gilead Sciences, Inc.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Ionis Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
ACADIA Pharmaceuticals Inc. vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Agios Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.